Condition: NSCLC (Non-small Cell Lung Cancer) · Thyroid Cancer · Solid Tumor Malignancies · Sponsor: Rigel Pharmaceuticals
An open-label drug-drug interaction study to evaluate the effects of pralsetinib (Gavreto) on the pharmacokinetics of a CYP450 probe substrate cocktail and, in female participants, a hormonal probe substrate, in participants with rearranged during transfection (RET) fusion- or mutation-positive solid tumors
This description comes directly from the study's public registry record.
Kay Patel · (650) 624-1100 · kpatel@rigel.com
Jill DeFratis · (650) 624-1100 · jdefratis@rigel.com
Always discuss trial participation with your own doctor first.
| Hospital Universitario San Pedro | Logroño, La Rioja, Spain | Recruiting |
| Hospital Universitario HM Sanchinarro | Madrid, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07704658